← All trials
NCT05132972
Phase 2/Phase 3Interventional
Trials that are a combination of phases 2 and 3.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 17, 2021
- Primary completion
- Nov 30, 2021
- Completion date
- Nov 30, 2021
- First posted
- Nov 24, 2021
- Last posted
- Nov 24, 2021
- Enrollment
- 42
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Badan Riset dan Inovasi Nasional, IndonesiaLead sponsor
- Padjadjaran UniversityOverall official - principal investigator
- Padjadjaran UniversityCollaborator
- Dr. Moewardi General Hospital, Surakarta, IndonesiaReponsible party - principal investigator
- Dr. Moewardi General Hospital, Surakarta, IndonesiaOverall official - principal investigator
- Dr. Moewardi General Hospital, Surakarta, IndonesiaCollaborator
- Dr. Sardjito General Hospital, Yogyakarta, IndonesiaOverall official - principal investigator
- Dr. Sardjito General Hospital, Yogyakarta, IndonesiaCollaborator
- PT Bifarma AdiluhungCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.